A new MassBio snapshot shows venture money and IPOs surging even as the industry sheds jobs — a split between thriving young companies and downsizing giants.
Older adults who got the Shingrix vaccine had notably lower dementia rates over four years, adding to a growing body of intriguing but not-yet-conclusive evidence.
The manufacturer will produce an AAV9 gene therapy for GM2 gangliosidosis — a group of fatal inherited disorders — developed with Queen’s University ahead of planned clinical trials.
An observational analysis of more than 31,000 patients tied one widely used class of blood-pressure pills to a 33% higher risk of serious kidney events — though researchers stress it cannot prove cause.
In lab-infected human immune cells, dexamethasone dialed down damaging inflammation from a stubborn lung infection while still letting the cells fight the bacteria.
Replimune’s oncolytic virus, given with nivolumab, won accelerated approval for melanoma that has progressed on immunotherapy — after two prior rejections.
The nationwide recall covers one lot of Tyenne (tocilizumab-aazg) injection after glass particles were found in the vials, a risk of irritation or vein inflammation.
A study of 402 adults found that physical activity and controlled blood sugar in midlife were associated with better preserved thinking skills decades later.
Analyzing antibody “fingerprints” across thousands of people, a deep-learning model spotted markers that flag who is likely to mount a weak vaccine response in advance.
A large Swedish study tracked hundreds of thousands of people and found that those who actually completed a mailed stool test were far less likely to die of colorectal cancer.
Iberdomide is the first approved CELMoD — a next-generation protein degrader — cleared in a three-drug combination for multiple myeloma as early as first relapse.
Nipocalimab wins FDA approval for warm autoimmune hemolytic anemia — a disease in which the immune system destroys the body’s own red blood cells — giving patients their first dedicated therapy.